A Common Asthma Drug May Help the Immune System Fight Cancer Again
Researchers have discovered that an asthma drug, montelukast, may help the immune system combat cancer by blocking a specific pathway used by tumors. This drug has shown promise in slowing tumor growth and restoring the immune system's ability to fight various cancers, including aggressive types like triple-negative breast cancer. The findings suggest that montelukast could be quickly tested in clinical trials due to its established safety profile.
- ▪Montelukast, a generic asthma drug, can block the CysLTR1 pathway that tumors use to suppress immune attacks.
- ▪In preclinical models, the drug slowed tumor growth and helped tumors respond to immunotherapy again.
- ▪Patients with higher CysLTR1 activity had poorer responses to immunotherapy and worse survival rates.
2 outlets in our directory ran this story, first to last over 23 hours. All of the coverage we found sits in one bucket: centre. That one-sidedness is itself worth noticing.
Discover Magazine files mainly under science. We currently carry 86 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Discover Magazine |
| Canonical URL | https://www.discovermagazine.com/a-common-asthma-drug-may-help-the-immune-system-fight-cancer-again-49120 |
| Publication time | Tue, 19 May 2026 18:55:00 GMT |
| Retrieval time | 2026-05-19T18:59:57.907Z |
| Last seen | 2026-05-19T18:59:57.907Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | DAho-jJxE5kM · 2 stories |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Some tumors do more than hide from the immune system. They can actually manipulate immune cells into helping cancer survive and spread. Now, researchers say an asthma drug may be able to interrupt that process.In a new study published in Nature Cancer, researchers at Northwestern Medicine found that many tumors appear to use a molecule called CysLTR1 to suppress immune attacks. When researchers blocked that pathway using montelukast in preclinical models, the generic version of the asthma drug Singulair, tumor growth slowed across several cancer types, and some tumors began responding to immunotherapy again.This could be especially important for aggressive cancers like triple-negative breast cancer, where immunotherapy often does not work as well as doctors hope.“When we turned off this…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Discover Magazine.
Discussion
0 commentsMore from Discover Magazine
